Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites

Journal of Hepatology

Volumn 25, Issue 4, 1996, Pages 481-490

  Gentilini, Paolo ^a   Villa, Giorgio La ^a   Marra, Fabio ^a   Carloni, Vinicio ^a   Melani, Lorenzo ^a   Foschi, Marco ^a   Cotrozzi, Giorgio ^a   Quartini, Mariano ^b   Chibbaro, Guido ^c   Tommasi, Alberto Candidi ^d   Bernareggi, Alberto ^e   Simoni, Antonella ^a   Buzzeli, Giampiero ^a   Laffi, Giacomo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c USL 10D   (Italy)

^d USL 9   (Italy)

^e Centro Ricerche Boehringer   (Italy)

Author keywords

Ascites; Cirrhosis; Diuretic resistant; Furosemide; Loop diuretics; Torasemide

Indexed keywords

ALDOSTERONE ANTAGONIST; CANRENOATE POTASSIUM; DIURETIC AGENT; FUROSEMIDE; HUMAN ALBUMIN; TORASEMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG URINE LEVEL; ECHOGRAPHY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY TEST; LIVER BIOPSY; LIVER CIRRHOSIS; MALE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; SODIUM RESTRICTION;

EID: 0030273235     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(96)80207-8     Document Type: Article

References (38)

1. Arroyo V, Epstein M, Gallus G, Gentilini P, Ring Larsen H, Salerno F. Refractory ascites in cirrhosis: mechanism and treatment. Gastroenterol Int. 2:1989;195-207.
2. Gentilini P, Laffi G, La Villa G, Marra F, Pinzani M, Carloni V, Foschi M, Casini Raggi V. Refractory ascites. Gastroenterol Int. 6:1994;33-39.
3. Gatta A, Angeli P, Caregaro L, Menon F, Sacerdote D, Merkel C. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology. 14:1991;231-236.
4. Pinzani M, Daskalopoulos G, Laffi G, Gentilini P, Zipser RD. Altered furosemide pharmacokinetics in chronic alcoholic liver disease with ascites contributes to diuretic resistance. Gastroenterology. 92:1987;294-298.
5. Fuller R, Hoppel C, Ingalls ST. Furosemide kinetics in patients with hepatic cirrhosis with ascites. Clin Pharmacol Ther. 30:1981;461-467.
6. Brater DC, Leinfelder J, Anderson S. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther. 42:1987;187-192.
7. Neugebauer G, Basenfelder E, Von Mollendorff E. Pharmacokinetics and metabolism of torasemide in man. Arzneimittel Forsch/Drug Res. 38:1988;164-166.
8. Lesne M, Clerkx-Braun F, P Duhoux, Van Ypersele de Strihou C. Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect. Int J Clin Pharmacol Ther Toxicol. 20:1982;382-387.
9. Knauf H, Spahn H, Rucker HM, Mutschler E. The loop diuretic torasemide in renal failure - kinetics and dynamics. Kruck F, Mutschler E, Knauf H. Torasemide: clinical pahrmacology and therapeutic applications. 1990;81-93 Gustav Fischer Verlag, Stuttgart.
10. Lesne M. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. Arzneimittel Forsch/Drug Res. 38:1988;160-163.
11. Knauf H, Mutschler E. Liver cirrhosis with ascites: pathogenesis of resistance to diuretic sand long-term efficacy and safety of torasemide. Cardiology. 84:1994;87-98. (suppl. 2).
12. Laffi G, Marra F, G Buzzelli, Azzena G, Meacci E, De Feo ML, La Villa G, Gentilini P. Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: a randomized, double-blind study. Hepatology. 13:1991;1101-1105.
13. Gerbes AL, Bertheau-Reitha U, Falkner C, Jungst D, Paumgartner G. Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. J Hepatol. 17:1993;353-358.
14. Crippa G, Cassi A, Vergani F. Renal excretory pharmacodynamics of diuretics in hepatic diseases. Reyes AJ. Nephrology and Hepatology. 1992;597-617 Gustav Fischer, Stuttgart. Diuretics: Clinical Pharmacology and Uses in Cardiovascular Medicine.
15. Elia G, Ferrari C, Degli Antoni A, Penna A, Fiaccadori F. A short-term clinical study of a new loop diuretic, torasemide, in cirrhosis. Ital J Gastroenterol. 21:1989;324-328.
16. 1α in juman urine: comparison of chromatography tecniques with radioimmunoassay and gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatography. 339:1985;1-9.
17. Laffi G, La Villa G, Cominelli F, Chelli M, Pinzani M, Tosti-Guerra C, Birardi A, Paladini S, Simoni A, Gentilini P. Purification of PGE2 in the urine of crrhotic patients: comparison of three chromatographic techniques. J Nucl Med Allied Sci. 32:1988;67-74.
18. Gentilini P, Laffi G, Meacci E, La Villa G, Cominelli F, Pinzani M, Buzzelli G. Effects of OKY 046, a thromboxanesynthase inhibitor, on renal function in nonazotemic cirrhotic patients with ascites. Gastroenterology. 94:1988;1470-1477.
19. Swezey SE, Meffin PJ, Tf Blaschke. Measurement of furosemide by High-Performance Liquid Chromatography. J Chromatography. 174:1979;469-473.
20. Gibaldi M, Perrier D. 2nd Edn. Pharmacokinetics. 1982;Marcel Dekker, New York.
21. Cochran PG, Cox GM. 2nd Edn. Experimental designs. 1968;John Wiley and Sons, New York.
22. Gentilini P, Laffi G. Pathophysiology and treatment of ascites and the hepatorenal syndrome. Bailliere's Clin Gastroenterol. 6:1992;581-607.
23. Puschett JB. Pharmacological classification and renal action of diuretics. Cardiology. 84:1994;4-13. (suupl 2).
24. Puschett JB. Sites and mechanisms of the renal actions of diuretics in man. Reyes AJ. Diuretics: clinical pharmacology and uses in cardiovascular medicine, nephrology and hepatology. 1992;117-130 Gustva Fischer, Stuttgart.
25. Brater DC. Pharmacokinetics and pharmacodynamics in cirrhosis. Epstein M. 3rd ed. The Kidney in liver disease. 551-571:1988;Williams and Wilkins, Bartimore.
26. Brater DC. Clinical pharmacology of loop diuretics. Drugs. 41:1991;41-22.
27. Sawhney VK, Gregory PB, Swezey SE, Blaschke TF. Furosemide disposition in cirrhotic patients. Gastroenterology. 81:1981;1012-1016.
28. Verbeeck RK, Patwardhan RV, Villenueve JP, Wilkinson GR, Branch RA. Furosemide disposition in cirrhosis. Clin Pharmacol Ther. 31:1982;719-725.
29. Fredric MJ, Pound DC, Hall SD, Brater DC. Furosemide absorption in patients with cirrhosis. Clin Pharmacol Ther. 49:1991;241-247.
30. Villenueve JP, Verbeeck RK, Wilkinson GR, Branch RA. Furosemide kinetics and dynamics in patients with cirrhosis. Clin Pharmacol Ther. 40:1986;14-20.
31. Schwartz S, Brater DC, Pound D, Green PK, Kramer WG, Rudy D. Bioavailiability, pharmacokinetics and pharmaco-dynamic of torasemide in patients with cirrhosis. Clin Pharmacol Ther. 54:1993;90-97.
32. Brunner G, Von Bergmann K, Hacker W, Von Molledorf E. Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. Arzneimittel Forsch/Drug Res. 38:1988;176-179.
33. Dodion L, Ambroes Y, Lameire N. A comparison of the pharmacokinetics and diuretic effect of two loop diuretics torasemide and furosemide, in normal volunteers. Eur J Clin Pharmacol. 31:1986;21-27.
34. Hammardlund-Udenaes M, Benet LZ. Furosemide pharmacokinetics and pharmacodynamics in health and disease - and update. J Pharmacokinet Biofarm. 17:1989;1-46.
35. Gonzales G, Arancibia A, Rivas MI, Caro P, Antezana C. Pharmacokinetics of furosemide in patients with hepatic cirrhosis. Eur J Clin Pharmacol. 22:1988;315-320.
36. Boles Ponto LL, Schoenwald RD, Furosemide (Frusemide). A pharmacokinetic/pharmacodynamic review. (Part II) Clin Pharmacokinet. 18:1990;461-471.
37. Dupont AG, Gerlo E, Van Der Niepen P, Laekeman G, Piepsz A. Renal pharmacodynamic effects of torasemide and furosemide in normal man. Arzneimittel Forsch/Drug Res. 38:1988;172-15.
38. Dunn MJ. Renal prostaglandins. Dunn MJ. Rena endocrinology. 1983;1-74 Williams and Wilkins, Baltimore.